December 7, 2011Open Access

Everolimus bei postmenopausalem hormonrezeptorpositivem fortgeschrittenem Brustkrebs

Key Points

Key points are not available for this paper at this time.

Abstract

Everolimus in Kombination mit einem Aromatasehemmer verbesserte das progressionsfreie Überleben bei Patienten mit hormonrezeptorpositivem fortgeschrittenem Brustkrebs, die zuvor mit nichtsteroidalen Aromatasehemmern behandelt wurden. (Finanziert von Novartis; BOLERO-2 ClinicalTrials.gov-Nummer, NCT00863655.)

Connected Papers

Building similarity graph...

Analyzing shared references across papers

Discussion

Authors

José Baselga

Mario Campone

Martine Piccart

Journals

New England Journal of Medicine

Actions

Institutions

Harvard University

University of Toronto

University of California, San Francisco

References and Citations

Connected Papers

Building similarity graph...

Analyzing shared references across papers

Everolimus bei postmenopausalem hormonrezeptorpositivem fortgeschrittenem Brustkrebs

Key Points

Abstract

Citation Network

Connected Papers

Discussion

Authors

Journals

Actions

Institutions

References and Citations

Citation Network

Connected Papers

Discussion

Cite this study

Also consider